Skip to main content
. 2021 Sep 13;9(9):1017. doi: 10.3390/vaccines9091017

Table 3.

Sociodemographic and clinical characteristics of individuals with COVID-19 infection participating in immunogenicity studies.

Variable N (%)
Total 180 (100.0)
Gender
Male 126 (70.0)
Female 54 (30.0)
Age (y)
Mean (SD) 59.6 (16.7)
≤54 63 (36.4)
55–64 42 (24.3)
≥65 68 (39.3)
Hospitalization
No 23 (12.8)
Yes 157 (87.2)
Symptoms
Symptomatic 171 (95.0)
Asymptomatic 9 (5.0)
Severity of Symptoms
Mild 60 (36.8)
Moderate 39 (23.9)
Severe 17 (10.4)
Critical 47 (28.8)